about
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisAdverse effects of antiretroviral therapy for HIV infectionSubstituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentComparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 careHLA-B*5701 testing to predict abacavir hypersensitivityPharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.First-line antiretroviral drug discontinuations in childrenFixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.Management of patients with HIV in the intensive care unitEarly upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.Abacavir hypersensitivity reaction: an update.Current trends in screening across ethnicities for hypersensitivity to abacavir.HIV-related liver disease: ARV drugs, coinfection, and other risk factors.Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.Antiretroviral therapy 2010 update: current practices and controversies.HLA alleles and drug hypersensitivity reactions.The structural basis of HLA-associated drug hypersensitivity syndromes.The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods.Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome.Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol.Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient.Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.Acute respiratory failure caused by phenytoin overdose.NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice.Reasons for early abacavir discontinuation in HIV-infected patients.Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.Acquired immunodeficiency syndrome in the intensive care unit: will human immunodeficiency virus-related admissions continue to decline?Precision medicine for HIV: where are we?Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
P2860
Q21999480-D6179B38-4BFE-4352-A5C0-CCEEBB3B40B5Q24617882-FE99881E-02CC-47C7-A3A5-AEDED211B73AQ24803596-2B6100D8-ED82-4696-A250-181D88CDACB9Q28546416-F5809912-4557-4D06-956C-21263740CF65Q33768961-763D560A-BB1C-4B7A-AF87-B765D808B032Q35873680-CEA54A22-AF8D-4437-8C82-8D34EC2310E9Q36278763-63D3B97E-82C4-4BAE-8082-7638EE1B013BQ36322100-43A37110-5388-4B17-A764-ABF80E513B05Q36341730-AB2A095C-F44C-4A37-9FFD-1248C8785218Q36343650-C352EF37-56B2-4786-A186-58BE7BA4B619Q36402487-E928D967-D680-480F-8758-A13254A60746Q36403151-EB2F2098-7D9E-481B-8AEB-D5A81AEA3530Q36813326-33038DA7-7327-44D6-BE77-B98966F44DCAQ37095697-2AD397FD-2779-4DBA-A341-944610A3E2B7Q37293999-43448878-70BA-4D56-AC7F-58BE3FFCDCA4Q37391122-33E0BFCA-E0F8-4C8A-8779-9B9AA27A242CQ37784777-AA3402C0-E919-432C-A95F-5C0EB76E26F0Q37910819-108A69C3-5F0C-4137-9461-9FFB89996F0CQ37963995-61D9B04E-6D6D-4BA9-9C37-995E236F54F3Q38050483-C1600033-2278-4982-935E-689F55E5B3F2Q38064446-E7D23371-0E4A-4790-BE01-ED575E4A86FBQ38122461-65E7E0AB-CBFE-412C-879C-DEA636D81C7BQ38239183-632EB5D4-21CB-4BAA-9BCD-7CFDB0580AC7Q40097257-ADE3285F-72EC-4DC4-8597-6BF8C1BC72C2Q40869976-AD073072-48EC-4F94-9FCC-03F0B150E033Q41747771-933706D1-2313-417D-B762-FE1CA849ECFCQ42854890-E5F8E24A-326E-4D9B-96E7-5F8169B89ED1Q44357874-F09A5A84-68F8-43C4-928B-517451471F65Q44602385-738B5CE3-AD55-46F0-B610-BE91DE9871FFQ45245260-CED076F3-0397-4C66-8E4C-6BC378F6B407Q45731497-2A1B2F60-F851-4D2A-99A2-0F36D311560DQ47569821-9A255B45-61ED-4666-A921-194CE63773FAQ49037532-6CECDB02-BE59-44A4-9403-13DACDDE0109Q57876986-E777B81C-3C8A-4F4E-8EC4-7489E4885837
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Abacavir hypersensitivity reaction.
@en
Abacavir hypersensitivity reaction.
@nl
type
label
Abacavir hypersensitivity reaction.
@en
Abacavir hypersensitivity reaction.
@nl
prefLabel
Abacavir hypersensitivity reaction.
@en
Abacavir hypersensitivity reaction.
@nl
P2860
P356
P1476
Abacavir hypersensitivity reaction.
@en
P2093
Ross G Hewitt
P2860
P304
P356
10.1086/339751
P407
P577
2002-03-19T00:00:00Z